Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA) EBITDA: ₽68.0 Mil (TTM As of Dec. 2023)


MIC:GEMA Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC MIC:GEMA
17 GF Score
Price ₽108.00
View Full Analysis

What is Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC EBITDA?

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC MIC:GEMA -1.73% 17 EBITDA is ₽68.0 Mil as of Dec. 2023. GuruFocus rates MIC:GEMA with a GF Score™ of 17/100.

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA for the three months ended in Dec. 2023 was ₽25.4 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₽68.0 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA per Share for the three months ended in Dec. 2023 was ₽1.70. Its EBITDA per share for the trailing twelve months (TTM) ended in Dec. 2023 was ₽4.56.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC  (MIC:GEMA) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC EBITDA Related Terms


Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC EBITDA Historical Data

* Premium members only.

The historical data trend for Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC EBITDA Chart

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA
Get a 7-Day Free Trial 129.26 140.02 150.53 116.44 160.00

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.72 36.39 42.65 0.00 25.36

MIC:GEMA vs FICO, SPSC, RDVT: EBITDA Comparison

For the Medical Care Facilities subindustry, Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC EV-to-EBITDA vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EV-to-EBITDA falls into.


MIC:GEMA
17GF Score
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC MIC:GEMA
EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2023, Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA was ₽160.0 Mil.

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA for the quarter that ended in Dec. 2023 is calculated as

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Dec. 2023, Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA was ₽25.4 Mil.

EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₽68.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of ₽68.0 Mil mean?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA) has a EBITDA of ₽68.0 Mil as of Dec. 2023. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC.
Is Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA too high?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's current EBITDA is ₽68.0 Mil. Overall, Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA compare to FICO and SPSC?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's EBITDA of ₽68.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Healthcare Providers & Services company?
A good EBITDA depends on the Healthcare Providers & Services industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's current EBITDA is ₽68.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC stock overvalued right now?
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA) has a current EBITDA of ₽68.0 Mil. The current EBITDA is ₽68.0 Mil. Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC (MIC:GEMA), the current EBITDA is ₽68.0 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC Business Description

Address Ulitsa Gubkina, d. 3, Building 1, Floor 1, Moscow, RUS, 119333
Interntl Medical Center of Biomaterials Processing & Cryostorag PJSC, through its subsidiary, is engaged in offering personal storage of cord blood stem cells in Russia and Eastern Europe. The services provided by the company include Cord Blood Cell Preservation, Program for the treatment of Cerebral Palsy, Cord Blood DNA isolation, and Umbilical Cord tissue, among others.
17GF Score

Get the complete analysis for MIC:GEMA

EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₽108.00
Price